The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2
Small · 2024
DOI: 10.1002/smll.202305148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Goeun Choi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, 31116, Republi…. Hauptthemen laut MEDLINE: Niclosamide, Antiviral Agents, SARS-CoV-2, COVID-19 Drug Treatment. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
The coronavirus disease 2019 (COVID‐19) pandemic is a serious global threat with surging new variants of concern. Although global vaccinations have slowed the pandemic, their longevity is still unknown. Therefore, new orally administrable antiviral agents are highly demanded. Among various repurposed drugs, niclosamide (NIC) is the most potential one for various viral diseases such as COVID‐19, SARS (severe acute respiratory syndrome), MERS (middle east respiratory syndrome), influenza, RSV (respiratory syncytial virus), etc. Since NIC cannot be effectively absorbed, a required plasma concentration for antiviral potency is hard to maintain, thereby restricting its entry into the infected cells. Such a 60‐year‐old bioavailability challenging issue has been overcome by engineering with MgO and hydroxypropyl methylcellulose (HPMC), forming hydrophilic NIC–MgO–HPMC, with improved intestinal permeability without altering NIC metabolism as confirmed by parallel artificial membrane permeability assay. The inhibitory effect on SARS‐CoV‐2 replication is confirmed in the Syrian hamster model to reduce lung injury. Clinical studies reveal that the bioavailability of NIC hybrid drug can go 4 times higher than the intact NIC. The phase II clinical trial shows a dose‐dependent bioavailability of NIC from hybrid drug suggesting its potential applicability as a game changer in achieving the much‐anticipated endemic phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Intelligent Nanohybrid Materials Laboratory (INML), Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, 31116, Republic of Korea.
- College of Science and Technology, Dankook University, Cheonan, 31116, Republic of Korea.
- Department of Nanobiomedical Science and BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University, Cheonan, 31116, Republic of Korea.
- Functional Biomaterials Research Center, Korea Research Institute of Institute of Bioscience and Biotechnology (KRIBB), Jeongeup, 34141, Republic of Korea.
- Institute of Pharmaceutical Science and Technology, College of Pharmacy, Hanyang University, Ansan, 15588, Republic of Korea.
- R&D Center, CnPharm Co. LTD., Seoul, 03759, Republic of Korea.
ORCID-Profile: Jin-Ho Choy
Förderung
- National Research Foundation of Korea
Zitieren
APA
Choi, G., Rejinold, N. S., Piao, H., Ryu, Y. B., Kwon, H. J., Lee, I. C., Seo, J. I., Yoo, H. H., Jin, G. W., & Choy, J. H. (2024). The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2. Small. https://doi.org/10.1002/smll.202305148
Vancouver
Choi G, Rejinold NS, Piao H, Ryu YB, Kwon HJ, Lee IC, et al. The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2. Small. 2024. doi:10.1002/smll.202305148
BibTeX
@article{Choi2024,
author = {Choi, Goeun and Rejinold, N Sanoj and Piao, Huiyan and Ryu, Young Bae and Kwon, Hyung-Jun and Lee, In Chul and Seo, Jeong In and Yoo, Hye Hyun and Jin, Geun-Woo and Choy, Jin-Ho},
title = {The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202305148}
}
EUVIMED